Skip to main content

Main navigation

  • About
    • Members
    • Staff
    • Annual Report
    • Rutgers-NPC 2023 Health Policy & Communications Fellowship
    • Health Policy Fellowship (Archive)
    • Contact Us
  • Topics
    • Health Spending
      • Understanding Health Spending
      • Low-Value Care
      • Health Spend Management
      • 340B Drug Pricing Program
    • Value Assessment
      • Value Assessment Frameworks
      • Value Assessment Methods
      • Elements of Value
    • Alternative Payment Models
      • Value-Based Contracts
      • Regulatory Barriers & Challenges
      • Paying for Cures
      • Accountable Care Organizations
      • Bundled Payments
      • Health Care Quality Measures
      • Clinical Pathways
    • Patient Centered Formulary & Benefit Design
      • High-Deductible Health Plans
      • Value-Based Insurance Design
      • Utilization Management & Step Therapy
      • Formulary Development
      • Patient Cost Sharing
      • Individual Treatment Effects & Personalized Access
    • Evidence for Decision Making
      • Real-World Data
      • Real-World Evidence
      • Good Practices for Evidence
    • Biopharma Innovation
      • Impact on Outcomes & Spending
  • Resources
    • Research
    • Letters & Comments
    • E.V.I.dently Today Blog
    • Events
    • CER Daily Newsfeed®
    • E.V.I.dently® Newsletter
    • Videos and Graphics
    • Press Room
      • NPC in the News
    • Stakeholder Resources
      • For Employers
      • For Patient Organizations
      • Going Below The Surface
  • Get Involved
    • Become a Member
    • Submit a Research Proposal
    • Start a Career
National Pharmaceutical Council

Offscreen menu

User account menu

  • Member Resources

How Reforms Can Enable Payment Innovation That Drives Value

  • Read more about How Reforms Can Enable Payment Innovation That Drives Value

Julie Patterson, PharmD, PhD

  • Read more about Julie Patterson, PharmD, PhD

Good Health Policy Requires High-Quality Evidence

  • Read more about Good Health Policy Requires High-Quality Evidence

An Oversimplified Drug Price Policy That Misses the Point

  • Read more about An Oversimplified Drug Price Policy That Misses the Point

The Impact of Price Regulation on Innovation: What the Research Shows

  • Read more about The Impact of Price Regulation on Innovation: What the Research Shows

Assessing the Effects of Biopharmaceutical Price Regulation on Innovation

  • Read more about Assessing the Effects of Biopharmaceutical Price Regulation on Innovation

NPC’s John O’Brien Discusses March-in, Co-pays, and Patient Access

  • Read more about NPC’s John O’Brien Discusses March-in, Co-pays, and Patient Access

Rochelle R. Henderson, PhD

  • Read more about Rochelle R. Henderson, PhD

Continuing Innovation for Rare Conditions Under the Orphan Drug Act 

  • Read more about Continuing Innovation for Rare Conditions Under the Orphan Drug Act 

Innovation Matters: Changing Lives for Cystic Fibrosis Patients

  • Read more about Innovation Matters: Changing Lives for Cystic Fibrosis Patients

Pagination

  • Page 1
  • Next page
Subscribe to Biopharmaceutical Innovation

Let's stay in touch.

Subscribe to Our Newsletter
© 2021 NPC. All rights reserved.

Footer Menu

  • Accessibility
  • Privacy Policy
  • Terms of Use
  • Contact Us

Footer Social Links Menu

  • Twitter
  • Linkedin
  • Youtube